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1133-153 Relationship Between Serum Cholesterol Levels and 
Development of Arterial Hypertension in the Population 
of the Brisighella Heart Study 
Claudia Borghi, Ada Dormi, Antonio Gaddi, Ettore Ambrosioini, St. Orsola-Malpighi 
Hospital, Bologna. Italy 
Background. Hypertension (HTN) and high serum cholesterol (HC) level are often com- 
bined in the same subject where they contribute to the overall cardiovascular risk proflle. 
HC is associated with a” impaired vasodilatory capacity and a” overexpression of vascu- 
lar angiotensin II receptors, which can contribute to the develpment of HTN. Aim of the 
present study was to investigate the role of HC, if any, in the development of HTN in the 
Brisighella Heart Study. 
Methods. 1230 “ormotensive subjects (SBP/DBPcl40/90 mmHg) enrolled in the Bri- 
slghella Heart Study in 1972 have been divided according to total serum cholesterol (T- 
Chol) tertiles and followed for 12 years to evaluate the proportion of patients developing 
HTN defined as SBP and/or DBP>l40/90 mmHg and/or therapy for HTN. 
Results. After adjustment for the main counfondlng factors (family history of HTN, age, 
BMI, sex, diabetes) the rate of HTN was significantly increased in subjects with T-Chol z 
239 mg/dl both after 8 (1980) and 12 (1984) years of follow-up (‘p<O.OOi YS. other sub- 
groups). The rate of development of HTN was enhanced in the two older subgroups of 
subjects (30-59 and z-59 years). 
Conclusion. These data suggest that HC could substantially contribute to the develop- 
ment of HTN and strongly support the wide role of lipid lowering drugs and particulary 
statins in the pnmary prevention of cardiovascular disease. 
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1133-154 Chronic Inflammation Adds to Metabolic Syndrome in 
the Prediction of Microalbuminuria 
Adrian W. Messerli, Gregory L. Pearce, Byron Hoogwerf, Dennis L. Sprecher, The 
Cleveland Clinic Foundation, Cleveland, OH 
Background: We have demonstrated that chronic inflammation, represented by c-reac- 
tive protein (CRP), predicts the presence of endothelial dysfunction, manifest as urinary 
albumin excretion. We hypothesize that the association of CRP with urine albumin is pre- 
dominately mediated through its correlation with the metabolic syndrome. Methods: 
Serum CRP and urine albumi”:creatinlne ratios (ACR) from 784 patients were analyzed 
to estimate age and gender adjusted relative risk of high CRP and metabolic syndrome 
for high ACR. High ACR was defined as >14.4 units (approximating the upper quartlIes of 
the HOPE trial) and high CRP was defined >0.20 mg/dL. Metabolic syndrome is defined 
per ATP Ill guidelines. Results: High ACR rates were 11% (301275) when neither high 
CRP “or metabolic syndrome were present, 23% (571243) when isolated high CRP was 
present, 23% (20187) when isolated metabolic syndrome was present and 35% (62079) 
when conjoint high CRP and metabohc syndrome were present. The odds ratio of 4.2 
when both factors were present was significantly higher than either isolated high CRP 
(p=O.Ol) or Isolated metabolic syndrome (p=O.OZ).(See table) Conclusion: The combined 
presence of elevated CRP and metabolic syndrome predicts a 4.fold increase in the 
occurence of elevated urinary albumin loss. This is consistent with both inflammation and 
traditional metabolic clinlcal risk negatively influencing endothelial function. 
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828FO-2 Plasma Neurohormones as Markers of Right Ventricular 
Overload and Predictors of Mortality in Acute 
Pulmonary Embolism 
laor I. Tulevski, Marye ten Wolde, Jasper W. M. Mulder. Dirk J. van Veldhuise”, Ernst E. 
van der Wall, Harry Buller, Barbara J M. Mulder, Academic Medical Center, Amsterdam, 
The Netherlands 
Background: Right ventricular (RV) function IS of major prognostic significance in 
patients with acute pulmonary embolism (PE). We studied the role of plasma neurohor- 
manes Brain Natrluretic Peptide (BNP) and Atrial Natriuretic Peptlde (ANP), and their 
potential to predict mortality in patients with acute PE. Methods: Plasma “eurohormone 
levels were measured in 114 patients (age 58(17) with acute PE within a” hour of pre- 
sent&ion after confirmed diagnosis by lung angiography and/or sclntigraphy. Twenty 
seven healthy age-matched volunteers served as controls (age 42(12)). Renal impalr- 
ment, atrial arrhythmias, preexisting RV pathology, and left ventricular dysfunction were 
exclusion criteria. In the patient group, survival was considered for a period of 30 
daysResults: Plasma BNP and ANP levels were significantly higher in patients with 
acute PE than in controls (BNP 34.4t61.9 pmol/L versus 3.1+3.7 pmoliL; p=O.Ol, and 
ANP 11.&17.3 pmol/L versus 4.6kl.9 pmollL; p=O.O3). Neurohormones were signifi- 
cantly higher in six patients who died within 30 days, compared to 108 patients who sur- 
vived (BNP 129.5*139.1 pmol/L versus 29.1*51.1 pmol/L; p=O.OOOl, and ANP 
34.lk53.9 pmol/L versus 10.6il2.3 pmol/L; p=O.OOl). 
Conclusions Neurohormone secretion is increased during acute PE in response to right 
ventricular overload. There was a significant relationship between presenting BNP and 
ANP levels, and 30.day mortality in patients with acute PE. Plasma “eurohormone levels 
may complement the diagnosis, treatment and in-hospital prognosis of patients with 
acute RV pressure overload such as see” in acute PE. 
4:30 p.m. 
828FO-3 Pro-Brain Natriuretic Peptide Predicts Severe 
Cardiovascular Events in Patients With Heart Disease 
Thomas Weber, Johann Auer. Elisabeth Lassnig, Marlina Strobl, Robert Berent, Bemd 
Eber, General Hospital of the Kreuzschwestern, Wels, Austria 
Background : The value of brain natrluretic peptide ( BNP ) in the diagnosis of heart fail- 
ure is well known. Moreover, BNP levels have prognostic significance after myocardial 
infarction and in heart failure. We tested the prognostic impact of BNP in a variety of dif- 
ferent heart diseases. 
Methods : We prospectively measured blood levels of n-terminal pro-BNP. using an 
immunoassay ( Elecsys pro BNP test, Roche diagnostics ), in patients undergoing car- 
diac catheterization in our laboratory for routine evaluation of heart disease. Follow-up 
data were collected at hospital discharge and after 3 months. 68 out of a total of 1730 
patients suffered from cardiovascular events ( event group ). As a control group served 
105 patients with a” uneventful course. Both groups were balanced with respect of age, 
sex, lipids, hypertension, diabetes, creatinine, smoking status, diagnosis, extent of coro- 
nary artery disease, left ventricular function, percutaneous interventions ( percentage, 
balloon and stent diameters, multivessel-interventions ) and medication use. For statis- 
tics we used Mann-Whitney U test and t-test, as appropriate. BNP values are given as 
mea” + / standard deviation. 
Results : The main diagnosis in both groups was coronary heart disease ( 79 vs 80 % ), 
fewer patients had valvular disease ( 15 vs 14 % ) or non-cardiac chest pain ( 6 % both 
groups ). Percutaneous interventions were performed in 45 (control group ) vs 50 (event 
group ) % of the patients. l&l patients had events during the first hospitalization ( includ- 
ing 12 myocardial Infarctions, 3 strokes and 5 deaths ), 50 patients had later events ( 
including 15 restenoses, 11 myocardial infarctions, 6 strokes and 23 deaths ). BNP-lev- 
els were higher in the event group than I” the control group ( 2958 + / - 7370 vs 1021 + / 
1591 pg/ml; p = 0,Ol ). BNP tended to be higher in patients with early events than with 
later events ( 5072 + ! - 11805 vs 2197 + i 4867 pg/ml, p = 0.16 ). In the event group. 
BNP was higher in patients who died than in patients with non-fatal complications ( 6017 
+/-11117vs1064+/-1947pg/ml,p=0,006). 
Conclusion : Pro-BNP is a” independent prognostic marker in a broad spectrum of 
patients with ischemic and valvular heart disease. 
4:45 p.m. 
828FO-4 What Causes Elevated B-Type Natriuretic Peptide in 
Patients Without Heart Failure? 
PeterA. McCullough, Philippe Gabriel Steg. Marie-Claude Aumont, Philippe Due, 
Torb~orn Omland. Catherine W. Knudsen, Richard M. Nowak, James McCord, Judd E. 
Hollander, Arne Westheim, Ala” 8. Storrow, William T. Abraham, Sumant Lamba, Alan 
H. Wu, Ala” S. Maisel, BNP MultInational Study Investigators, William Beaumont 
Hospltal, Royal Oak, MI, University of California, San Diego School of Medicine, 
Veterans Affairs Medical Center, San Diego, CA 
Introduction: Bedside plasma B-type “atriuretic peptide (BNP) can be used to reliably 
identify decompensatecf congestive heart failure (CHF) in patients presenting in the 
emergency department (ED) with acute dyspnea. Left ventricular (LV) systolic and dias- 
tolic failure, as well as increased LV mass, are asssociated with increased BNP levels. 
Widespread use of BNP after its approved use as a diagnostic aid I” CHF. and as a prog- 
nostic indicator I” acute coronary syndromes, has raised the issue of what other disease 
processes can cause a markedly elevated BNP? 
Methods The BNP Multinational Study was a seven-center prospective study of 1586 
patients presenting to the ED with acute dyspnea and had blinded BNP levels measured 
with a rapid, point-of-care device on arrival. The reference standard for CHF was adjudi- 
cated by two independent cardiologists, also blinded to BNP results. who reviewed all 
clinical data and standardized CHF scores. 
Results: A total of 717 subjects (mean age 57.6 years, 54.3% male) had no history of 
CHF or LV dysfunction and were confirmed by two cardiologist to 9 have CHF. Of 
these, 40/717 (5.6%) and 15fll7 (2.1%) were found to have BNP values 2 500 and 2 
1000 pg/ml, respectively. Of these 40 with BNP 2 500 pglml, 25.0% had a history of 
ischemic heail disease, 12.5% with ischemic changes by electrocardiogram, 42.4% had 
a hlstory of asthma or chonic obstructive pulmonary disease (COPD), and 1 .O% with car 
pulmonale. Physical exam findings included: elevated jugular venous pressure in 15%. 
hepatic congestion in 17.5%. and peripheral edema in 50.0%. Chest x-rays were abnor- 
mal in 52.2% and oxygen saturations were 5 90% in 14.8% of subjects. The most com- 
mon final diagnoses were: asthma or COPD with right ventricular strain, pneumonia, 
pulmonary embolism, anemia, cardiac ischemia, and sepsis. Chronic kidney disease 
